Rituximab in the Treatment of Patients With Bullous Pemphigoid

Completed · Phase 1/Phase 2

Conditions studied: Bullous Pemphigoid

In brief

This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.

Key facts

Study ID

NCT00286325

Run by

Duke University

People needed

8

Starts

2005-03-01

Expected to finish

2010-03-01

Last updated by the study team

2013-04-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with autoimmune blistering skin diseases with clinical, histologic and immunological criteria confirming the diagnosis of bullous pemphigoid
• Ongoing disease activity on 17.5 mg/day of prednisone or more

You may not qualify if…

• Current use of other immunosuppressive therapy such as azathioprine, cytoxan or mycophenolate mofetil within the last 4 weeks.

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.